A Study to Compare the Pharmacokinetic Profiles of DW224aa and DW224a

Phase 1 Completed 32 enrolled Seoul National University Hospital Dong Wha Pharmaceutical Co. Ltd. · collab

RandomizedCrossoverOpen-label

Summary

The purpose of this study is to compare and explore pharmacokinetics of zabofloxacin, the main component of DW224aa(Test drug) and DW224a(Reference drug).

Timeline

Start: 2011-04
Primary completion: 2011-05
Completion: —

Publications

Han H, Kim SE, Shin KH, Lim C, Lim KS, Yu KS, Cho JY. Comparison of pharmacokinetics between new quinolone antibiotics: the zabofloxacin hydrochloride capsule and the zabofloxacin aspartate tablet. Curr Med Res Opin. 2013 Oct;29(10):1349-55. doi: 10.1185/03007995.2013.825591. Epub 2013 Aug 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Zabofloxacin	Small molecule	366.5 mg	Oral
Subject	Zabofloxacin	Small molecule	366.7 mg	Oral

Indications

No indication recorded.